Standardization of Quantitative Evaluation and Establishment of New Biomarkers in Radioactive Iodine Therapy for Thyroid Cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K08075
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52040:Radiological sciences-related
• Research Institution: Hamamatsu University School of Medicine
• Principal Investigator: Konishi Kenta 浜松医科大学, 医学部, 助教 (30529607)
• Co-Investigator(Kenkyū-buntansha): 中村 和正 浜松医科大学, 医学部, 教授 (20284507) ; 小松 哲也 浜松医科大学, 医学部, 准教授 (50334769)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 甲状腺癌 / 放射性ヨウ素内用療法 / 補助療法 / 定量評価 / SUV / kBq/ml

Outline of Final Research Achievements

In the adjuvant therapy of radioactive iodine (RAI) following thyroid cancer surgery, quantitative evaluation of the thyroid bed was conducted. The group with disappearance of thyroid bed uptake showed significantly higher kBq/ml compared to the group without disappearance. On the other hand, although the SUV (standardized uptake value) tended to be higher in the group with disappearance, there was no significant difference. This study indicates that a new quantitative parameter, radiation dose (kBq/ml), may have the potential to serve as a predictive indicator for radioactive iodine therapy.
Furthermore, in an experimental study using a phantom, the relationship between the actual radioactivity of I-131 and the measured radioactivity by Syngo.via was confirmed to be approximately 30% of the actual radioactivity when a threshold of 40% was set.

Free Research Field

放射線腫瘍学

Academic Significance and Societal Importance of the Research Achievements

本研究により直接研究対象者に利益が生じることはないが、本研究の結果により、今後の放射性ヨウ素内用療法補助療法を施行する症例において、SUVやkBq/ml等の定量化指標が新たなバイオマーカーとして治療効果予測や予後予測の指標になる可能性が期待できる。
甲状腺床のみならず、転移巣に対する効果と定量値との関係については、さらなる検討が必要である。